Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.

Bousman CA, Dunlop BW.

Pharmacogenomics J. 2018 Sep;18(5):613-622. doi: 10.1038/s41397-018-0027-3. Epub 2018 May 25.

PMID:
29795409
2.

En alvorlig deprimert kvinne med uvanlig respons på antidepressiver.

Sundfjord N, Tran GT, Haver B.

Tidsskr Nor Laegeforen. 2018 Apr 13;138(7). doi: 10.4045/tidsskr.16.1134. Print 2018 Apr 17. Norwegian. No abstract available.

3.

Optimization of Antidepressant use with Pharmacogenetic Strategies.

Torrellas C, Carril JC, Cacabelos R.

Curr Genomics. 2017 Oct;18(5):442-449. doi: 10.2174/1389202918666170426164940.

4.

Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.

Health Quality Ontario .

Ont Health Technol Assess Ser. 2017 Apr 11;17(4):1-39. eCollection 2017. Review.

5.

Complications of Psychotropic and Pain Medications in an Ultrarapid Metabolizer Patient at the Upper 1% of Cytochrome P450 (CYP450) Function Quantified by Combinatorial CYP450 Genotyping.

Ruaño G, Larsen K, Kocherla M, Graydon JS, Kost J.

J Pain Palliat Care Pharmacother. 2017 Jun;31(2):126-138. doi: 10.1080/15360288.2017.1304494. Epub 2017 May 16.

PMID:
28506184
6.

Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study.

Dong YH, Bykov K, Choudhry NK, Donneyong MM, Huybrechts KF, Levin R, Schneeweiss S, Gagne JJ.

J Clin Psychopharmacol. 2017 Apr;37(2):200-209. doi: 10.1097/JCP.0000000000000658.

PMID:
28129313
7.

Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.

Kim S, Yun YM, Chae HJ, Cho HJ, Ji M, Kim IS, Wee KA, Lee W, Song SH, Woo HI, Lee SY, Chun S.

Ann Lab Med. 2017 Mar;37(2):180-193. doi: 10.3343/alm.2017.37.2.180.

8.

Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9.

Nagy A, Bűdi T, Temesvári M, Szever Z, Szabó PT, Monostory K.

Epilepsy Behav Case Rep. 2015 Sep 22;4:86-7. doi: 10.1016/j.ebcr.2015.08.006. eCollection 2015.

9.

In vitro inhibition and induction of human cytochrome P450 enzymes by SIPI5357, a potential antidepressant.

Fan G, Cao Y, Yang J.

Biopharm Drug Dispos. 2015 Sep;36(6):364-372. doi: 10.1002/bdd.1947. Epub 2015 May 4.

PMID:
25776278
10.

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.

Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, Dechairo BM, Winner JG.

Pharmacogenomics J. 2015 Oct;15(5):443-51. doi: 10.1038/tpj.2014.85. Epub 2015 Feb 17.

PMID:
25686762
11.

Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95.

Kong H, Song JK, Yenugonda VM, Zhang L, Shuo T, Cheema AK, Kong Y, Du GH, Brown ML.

Mol Pharm. 2015 Feb 2;12(2):393-402. doi: 10.1021/mp5003569. Epub 2015 Jan 20.

12.

Searching the cytochrome p450 enzymes for the metabolism of meranzin hydrate: a prospective antidepressant originating from Chaihu-Shugan-San.

Huang X, Guo Y, Huang WH, Zhang W, Tan ZR, Peng JB, Wang YC, Hu DL, Ouyang DS, Xiao J, Wang Y, Luo M, Chen Y.

PLoS One. 2014 Nov 26;9(11):e113819. doi: 10.1371/journal.pone.0113819. eCollection 2014.

13.

The effects of acute hydrogen sulfide poisoning on cytochrome P450 isoforms activity in rats.

Wang X, Chen M, Chen X, Ma J, Wen C, Pan J, Hu L, Lin G.

Biomed Res Int. 2014;2014:209393. doi: 10.1155/2014/209393. Epub 2014 Mar 26.

14.

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.

Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D.

Int Rev Psychiatry. 2013 Oct;25(5):509-33. doi: 10.3109/09540261.2013.825579. Review.

PMID:
24151799
15.

Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine.

Bymaster FP, Chao P, Schulze H, Tran PV, Marshall RD.

Drug Metab Lett. 2013 Mar;7(1):23-33.

PMID:
23826879
16.

Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.

Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadić A.

Ther Drug Monit. 2013 Jun;35(3):279-82. doi: 10.1097/FTD.0b013e31828816e0.

PMID:
23666577
17.

Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression.

Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A.

Transl Psychiatry. 2013 Mar 19;3:e242. doi: 10.1038/tp.2013.2.

18.

The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.

Höfer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, Konstantinidis A, Linotte S, Mendlewicz J, Souery D, Zohar J, Juven-Wetzler A, Montgomery S, Kasper S.

Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):385-91. doi: 10.1007/s00406-012-0375-y. Epub 2012 Oct 19.

PMID:
23081704
19.

Fluoxetine pharmacogenetics in child and adult populations.

Blazquez A, Mas S, Plana MT, Lafuente A, Lázaro L.

Eur Child Adolesc Psychiatry. 2012 Nov;21(11):599-610. doi: 10.1007/s00787-012-0305-6. Epub 2012 Jul 12. Review.

PMID:
22791347
20.

Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.

Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M.

Drug Metab Dispos. 2012 Sep;40(9):1778-84. doi: 10.1124/dmd.112.045237. Epub 2012 Jun 11.

Supplemental Content

Loading ...
Support Center